ModifiedUnitedHealthcarePolicy CS082KY.12

Neurophysiologic Testing and Monitoring (for Kentucky Only)

Medical policy governing neurophysiologic/electrodiagnostic testing and monitoring for members in Kentucky, including which tests are considered proven and medically necessary versus unproven and not medically necessary.

Policy Summary

PayerUnitedHealthcare

PolicyNeurophysiologic Testing and Monitoring (for Kentucky Only)

Policy CodePolicy CS082KY.12

Change TypeAdded pediatric proven indicationsclarified NCS without needle EMG stanceremoved codes

Effective DateMay 1, 2026

Next Review Date

Key ActionWhen performing NCS/EMG, document clinical indication and supervision and ensure testing is performed to accepted standards to support coverage.

SourceLink

POLICY UPDATE CHANGES

Added language indicating nerve conduction studies (with or without standard late responses) and for neuromuscular junction testing when performed with needle EMG are proven and medically necessary for peripheral neuropathy/polyneuropathy, plexopathy, neuromuscular junction disorders, and myopathy for members under 18 years of age.

Clarified conditions (radiculopathy, treatment guidance for muscle localization, and specific clinical indications such as anticoagulation, lymphedema, and carpal tunnel evaluation) where nerve conduction studies without needle EMG may be considered, and specified that nerve conduction studies for other conditions and several automated/point-of-care devices are unproven and not medically necessary.

Added language indicating nerve conduction studies with or without standard late responses and for neuromuscular junction testing when performed with needle electromyography are proven and medically necessary for specific disorders in members under 18 years of age.

Clarified that nerve conduction studies without needle EMG are unproven and not medically necessary for conditions other than listed indications (e.g., radiculopathy, treatment guidance, certain clinical indications such as anticoagulation, lymphedema, evaluation for carpal tunnel).

Removed CPT/HCPCS codes 95999 and A9279 from the applicable codes section.

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect current information and archived previous policy version CS082KY.11.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

05/01/2026Revision effective date

4Pediatric proven indications added

UnprovenAutomated point-of-care distal-only NCS

2CPT/HCPCS codes removed

20+Applicable codes listed

Coverage and Medical Necessity Criteria

Proven and Medically Necessary Tests

Covered when ANY of the following clinical situations are present with appropriate correlation:

Indications for NCS with or without needle EMG: Nerve conduction studies with or without standard late responses (e.g., F-wave and H-reflex) and neuromuscular junction testing when performed in conjunction with needle electromyography are proven and medically necessary for any of the following known or suspected disorders: peripheral neuropathy/polyneuropathy (e.g., inherited, metabolic, traumatic, entrapment syndromes); plexopathy; neuromuscular junction disorders (e.g., myasthenia gravis); myopathy; motor neuron disease; radiculopathy (cervical, thoracic, or lumbosacral); or for treatment guidance such as muscle localization for botulinum toxin injections.

NCS without Needle EMG — Specific Indications

Covered in lieu of needle EMG when specified clinical risk factors are present:

NCS without needle EMG indications: Nerve conduction studies with or without standard late responses when performed without needle electromyography may be medically necessary for individuals who have one of the above known or suspected disorders AND have one of the following clinical indications: are treated with anticoagulants; have lymphedema; or are being evaluated for carpal tunnel syndrome.

Unproven / Not Medically Necessary

Not medically necessary / Unproven due to insufficient evidence:

Unproven tests: Macro-EMG (macroelectromyography); non-invasive automatic/portable/automated point-of-care nerve conduction monitoring systems that test only distal motor latencies and conduction velocities; physiologic wearable seizure or movement disorder monitors (accelerometer, electrodermal, gyroscope based devices); SEMG-based seizure monitoring systems; surface electromyography (SEMG); surface mechanomyography (sMMG); quantitative sensory testing (including monofilament, pressure-specified sensory testing, computer-assisted sensory examinations, current perception threshold/CPT testing and CPT codes 0106T-0110T); and visual evoked potential testing for glaucoma are considered unproven and not medically necessary due to insufficient evidence of efficacy.

Indications for EDX testing (per AANEM guidance)

Covered when testing is medically indicated and ALL of the following apply:

EDX basic prerequisites: Development of a differential diagnosis based upon appropriate history and physical examination; testing is medically indicated; testing is performed using appropriate equipment (not screening-only devices); testing is performed by a physician or a trained technician under direct physician supervision; and EMG is performed by a trained physician. One physician should supervise and perform all components of the examination.

From AANEM recommended policy and model policy

Clinical indications where EDX testing is indicated

EDX testing is appropriate when ANY of the following clinical scenarios are present:

Indicated conditions: Focal neuropathies/entrapment/compressive lesions (e.g., carpal tunnel, ulnar neuropathy, root lesions) for localization; traumatic nerve lesions for diagnosis and prognosis; generalized neuropathies (diabetic, uremic, metabolic, toxic, hereditary, immune-mediated); neuromuscular junction disorders (e.g., myasthenia gravis); symptom-based presentations such as limb pain, weakness, sensory disturbance or paresthesia when appropriate pre-test evaluations are inconclusive; radiculopathy (cervical, thoracic, lumbosacral); plexopathy (idiopathic, trauma, inflammatory or infiltrative); myopathy (including inflammatory and congenital myopathies); and precise muscle localization for injections (e.g., botulinum toxin).

List from AANEM model policy

When EDX testing may be low yield

EDX testing is likely of low yield when ALL of the following are met:

Low-yield scenario: Symptoms and physical findings are mild; findings are symmetric, distal, and predominantly sensory; there is a known cause (for example, diabetes mellitus); and there is little suspicion of a coexisting nerve disorder.

From AANEM Distal Symmetric Polyneuropathy guidance

Professional Society Guidance and Evidence Summary

Professional society positions and evidence summaries relevant to device and QST use

ILAE-IFCN wearable recommendation: The ILAE-IFCN Working Group conditionally recommends using clinically validated wearable devices for automated detection of generalized tonic-clonic seizures (GTCS) and focal bilateral tonic-clonic seizures (FBTCS) when significant safety concerns exist and alarms can result in rapid intervention (within ~5 minutes), particularly for unsupervised individuals who do not share a bedroom (weak/conditional recommendation).

ILAE/IFCN Working Group, Beniczky 2021

ILAE-IFCN limitation: The ILAE-IFCN Working Group does not recommend current wearable devices for seizure types other than GTCS/FBTCS (weak/conditional).

AAN on QST: The American Academy of Neurology (AAN) notes QST may be useful in clinical and research settings but should not be used as the sole diagnostic method; class I evidence for effectiveness in specific disorders is lacking, with Level B support for vibration/thermal testing in diabetic neuropathy and Level U for preclinical detection.

AAN 2003 report reaffirmed 2025

Coverage considerations by modality

Coverage stance is evidence-limited and modality-specific; summarize where technologies are considered investigational or lack sufficient evidence:

QST: Quantitative Sensory Testing (QST) is a psychophysical method that can assess large- and small-fiber sensory modalities but is highly dependent on testing methodology, instrument calibration, and full subject cooperation; QST does not localize dysfunction and should not be used as the sole diagnostic test in clinical decision-making unless reproducible instruments and protocols are used.

AAN/AAEM/AANEM reviews

sNCT: Current perception threshold/sensory nerve conduction threshold testing (sNCT) is considered investigational per AANEM model policy and may be treated as not established for coverage purposes.

AANEM model policy

sEMG for seizure monitoring: Surface EMG (sEMG) wearable devices demonstrate feasibility for GTCS detection with variable sensitivity and substantial false alarm rates; evidence is limited and device performance varies by placement and algorithm, so routine coverage is not supported pending further validation.

Limited prospective trials and variable FAR reported

Proven Indications (Members Under 18)

Added coverage statements for members under 18 years of age:

Proven and medically necessary NCS+EMG indications (members <18): Nerve conduction studies with or without standard late responses and neuromuscular junction testing when performed in conjunction with needle electromyography are proven and medically necessary for members under 18 with peripheral neuropathy/polyneuropathy (including inherited, metabolic, traumatic, entrapment syndromes), plexopathy, neuromuscular junction disorders (e.g., myasthenia gravis), or myopathy.

NCS Without Needle EMG and Device-Specific Stance

Coverage/stake clarifications for nerve conduction studies without needle EMG and device-specific stance:

Situations where NCS without needle EMG may be performed: Nerve conduction studies with or without standard late responses when performed without needle electromyography may be considered for individuals with radiculopathy (cervical, thoracic, or lumbosacral); for treatment guidance such as muscle localization for botulinum toxin injections; and for individuals with specific clinical considerations including anticoagulation, lymphedema, or evaluation for carpal tunnel syndrome.

Not medically necessary / Unproven: Nerve conduction studies for conditions other than those specified as proven; non-invasive automatic/portable/automated point-of-care NCS systems that test only distal motor latencies and conduction velocities; macro-EMG; surface EMG; sMMG; SEMG-based seizure monitoring; wearable physiologic monitoring devices for seizure/movement disorders; QST modalities listed; and visual evoked potential testing for glaucoma are considered unproven and not medically necessary due to insufficient evidence of efficacy.

Coverage and Medical Necessity Criteria

Coverage stance summarized from policy changes and summaries

Pediatric proven NCS indications: For members under 18, nerve conduction studies with or without standard late responses and neuromuscular junction testing when performed with needle electromyography are proven and medically necessary for peripheral neuropathy/polyneuropathy, plexopathy, neuromuscular junction disorders, and myopathy.

Situations where NCS without needle EMG may be considered: Nerve conduction studies without needle EMG may be considered for radiculopathy (cervical/thoracic/lumbosacral), for muscle localization to guide injections (e.g., botulinum toxin), and for individuals on anticoagulants, with lymphedema, or being evaluated for carpal tunnel syndrome.

Unproven/not medically necessary tests: Nerve conduction studies for other conditions not listed as proven; automated point-of-care distal-only NCS systems; macro-EMG; wearable seizure/movement monitors; SEMG; sMMG; quantitative sensory testing modalities listed; and visual evoked potential testing for glaucoma are unproven and not medically necessary due to insufficient evidence of efficacy.

This policy explicitly excludes intraoperative neurophysiologic testing from its scope. Visual evoked potential testing for diagnosing or evaluating glaucoma is listed as unproven and not medically necessary. Other modalities called out in the exclusions include macro‑EMG, non‑invasive automated/portable point‑of‑care NCS systems that test only distal motor latencies and conduction velocities, physiologic wearable seizure/movement monitors, SEMG‑based seizure monitoring systems, surface EMG, surface mechanomyography (sMMG), and quantitative sensory testing (including monofilament and CPT methods).

The policy describes the evidence for Macro‑EMG as weak: few studies exist and available data do not demonstrate consistent patient‑relevant outcomes. As a result, macro‑EMG is categorized as unproven and not medically necessary pending further robust studies.

Wearable seizure detection devices are supported only for specific seizure types. The ILAE‑IFCN recommends clinically validated wearables for automated detection of generalized tonic‑clonic seizures (GTCS) and focal bilateral tonic‑clonic seizures (FBTCS) in settings with safety concerns (weak/conditional). The group does not recommend current wearable devices for other seizure types; such uses remain unproven and are not supported by the policy.

Quantitative Sensory Testing (QST) is described as a useful psychophysical tool in some settings but has important limitations. The AAN and AANEM both note that QST results depend heavily on methodology, instrument calibration, and subject cooperation; the AAN states that QST should not be used as the sole method for diagnosis of pathology. Monofilament testing in particular has limited sensitivity for diabetic peripheral neuropathy (pooled sensitivity ~0.53) and therefore should not be relied upon alone for screening or definitive diagnosis.

Certain emerging modalities are designated investigational or lacking sufficient evidence. The AANEM regards current perception threshold/sensory nerve conduction threshold testing (sNCT) as investigational per its model policy; surface mechanomyography (sMMG) with IMU sensors has few published studies and its impact on health outcomes is uncertain. These sNCT and some sMMG applications are therefore treated as investigational / unproven in this policy.

Automated or portable point‑of‑care nerve conduction devices receive specific caution: preliminary studies exist, but evidence is limited and largely from small case series. Non‑invasive automatic, portable, or automated point‑of‑care NCS systems that test only distal motor latencies and conduction velocities are considered unproven and not medically necessary for electrodiagnostic testing in this policy.

The policy does not address intraoperative neurophysiologic testing and therefore makes no coverage determinations for intraoperative monitoring; statements elsewhere in the document reiterate that intraoperative neurophysiologic testing is outside the scope of this policy.

All modalities listed under the policy section 'Other Neurophysiological Testing' are considered unproven and not medically necessary due to insufficient evidence. Additionally, the policy clarifies that nerve conduction studies performed for conditions not listed as proven indications (i.e., outside the specified neuropathy, plexopathy, neuromuscular junction disorder, myopathy, radiculopathy, or other enumerated uses) are unproven and not medically necessary and may be subject to denial.

The policy cautions against substituting simplified or point‑of‑care approaches for comprehensive electrodiagnostic studies. Specifically, using point‑of‑care NCS systems or macro‑EMG as substitutes for standard NCS and needle EMG is not supported by robust evidence and is therefore considered unproven; such substitutions are not endorsed as equivalent to standard studies.

Monofilament testing demonstrates limited sensitivity for detecting diabetic peripheral neuropathy (pooled sensitivity ~0.53) and a relatively higher specificity; because of this limited sensitivity the policy cautions that monofilament tests should not be used alone as the screening or diagnostic standard for diabetic peripheral neuropathy.

AANEM practice guidance indicates that current evidence is insufficient to determine the clinical utility of surface EMG (sEMG) for certain diagnostic purposes, including reliably distinguishing neuropathic versus myopathic processes and detecting several specific neuromuscular diseases. Consequently, the policy treats many sEMG applications as lacking sufficient evidence for routine clinical use.

The policy states that nerve conduction studies performed for conditions other than those explicitly identified as proven indications are unproven and not medically necessary. This includes NCS ordered outside the listed diagnoses and scenarios and reiterates that claims for such testing may be subject to denial.

Non‑invasive automated point‑of‑care systems that measure only distal motor latencies and conduction velocities are explicitly considered unproven and not medically necessary for electrodiagnostic purposes. The policy highlights that while some devices have FDA 510(k) clearance, available peer‑reviewed evidence is insufficient to support equivalence to comprehensive NCS/EMG studies.

Applicable Codes and Coding Notes

Covered/Referenced CPT CodesCPT

0106T	QST per extremity; touch pressure
0107T	QST per extremity; vibration stimuli
0108T	QST per extremity; cooling stimuli
0109T	QST per extremity; heat-pain stimuli
0110T	QST per extremity; other stimuli
0464T	Visual evoked potential for glaucoma
0778T	Surface mechanomyography (sMMG) with IMU
95860	Needle EMG; 1 extremity
95861	Needle EMG; 2 extremities
95863	Needle EMG; 3 extremities

1–10 of 21

1/3

Referenced HCPCS / Other CodesHCPCS

A9280	Alert or alarm device, not otherwise classified
G0255	Current perception threshold/sensory nerve conduction test (SNCT) per limb
S3900	Surface electromyography (EMG)

Removed Codesmixed

95999	Removed — Unspecified neurodiagnostic procedure
A9279	Removed — Monitoring/alert device (no longer valid)

QST and SNCT Codes (referenced)CPTExperimental

0106T	QST touch pressure
0107T	QST vibration
0108T	QST cooling
0109T	QST heat-pain
0110T	QST other stimuli
G0255	Current perception threshold / SNCT (referenced HCPCS)

Note

Not specified in this section.

Not specified in this section: No step therapy directives are described and there are no additional step-therapy or quantity-limit rules specified here.

Provider Requirements, Documentation, and Billing Guidance

Documentation Required

Document medical indication and supervision for NCS/EMG

Electrodiagnostic testing (NCS/EMG) must be medically indicated and performed to accepted standards; document the clinical indication and that testing used appropriate equipment and physician supervision per AANEM guidance.

Ensure testing is medically indicated and part of a differential diagnosis based on history and physical exam.
Use equipment that assesses all signal parameters (screening-only devices are not acceptable).
Testing should be performed by a physician or a trained technician under direct physician supervision; needle EMG must be performed by a trained physician.

Documentation Required

Document device data when used to guide management

When device-derived objective measurements (e.g., PKG, KinetiGraph, biosensor patches) are used to inform management, document device type, recording duration, device-derived findings that influenced management, and clinician interpretation correlating device data with clinical status.

Background and Evidence Summary

Neurophysiologic testing—nerve conduction studies (NCS) and electromyography (EMG)—assesses peripheral nerve conduction and muscle electrical responses and is intended to complement, not replace, a thorough history and physical examination. The policy emphasizes that electrodiagnostic evaluation typically integrates both NCS and needle EMG, with late responses (e.g., F‑wave, H‑reflex) included when performed, to help localize and characterize peripheral nerve and muscle disorders.

Definitions and Test Descriptions

Needle EMG — Definition

DefinitionNeedle electromyography (NEMG) requires insertion of needles through the skin to record electrical activity from individual muscles, used to determine whether weakness arises from nerve, neuromuscular junction, or muscle pathology.

PurposeHelpful in evaluating muscle and motor unit function and differentiating neuropathic from myopathic processes.

Performance noteNeedle EMG studies are interpreted in real time as they are being performed per AANEM practice, and EMG must be performed by a trained physician.

SEMG — Surface electromyography definition

DefinitionSurface electromyography (SEMG) uses electrodes placed on the skin to measure electrical activity of underlying muscle noninvasively.

Applications

Policy Revision History

2026-05-01material_revisionLatest

Added pediatric coverage: Nerve conduction studies (with or without standard late responses) and neuromuscular junction testing when performed with needle EMG are proven and medically necessary for peripheral neuropathy/polyneuropathy, plexopathy, neuromuscular junction disorders, and myopathy for members under 18 years of age.

2026-05-01clarification

Clarified situations where NCS without needle EMG may be considered (radiculopathy; treatment guidance such as muscle localization for botulinum toxin; and specific clinical indications including anticoagulation, lymphedema, and carpal tunnel evaluation) and restated that NCS for other conditions and certain automated/point-of-care distal-only NCS systems are unproven and not medically necessary.

Policy Summary

PayerUnitedHealthcare

PolicyNeurophysiologic Testing and Monitoring (for Kentucky Only)

Policy CodePolicy CS082KY.12

Change TypeAdded pediatric proven indicationsclarified NCS without needle EMG stanceremoved codes

Effective DateMay 1, 2026

Next Review Date

Key ActionWhen performing NCS/EMG, document clinical indication and supervision and ensure testing is performed to accepted standards to support coverage.

SourceLink

On This Page

AANEM on QST and sNCT: AANEM states QST is a reliable psychophysical test of large- and small-fiber modalities but is highly dependent on methodology, calibration, and subject cooperation; the current perception threshold/sensory nerve conduction threshold test (sNCT) is considered investigational by AANEM model policy.

AANEM technical reviews and model policy

sEMG for other clinical uses: Evidence for sEMG applications in respiratory, musculoskeletal, ALS, TMD, and other assessments is mixed or insufficient to conclude broad clinical utility; further standardized studies are needed.

sMMG with IMU sensors: Surface mechanomyography (sMMG) with inertial measurement unit (IMU) sensors has few published studies and no demonstrated effect on health outcomes; evidence insufficient for routine coverage.

Visual Evoked Potentials (icVEP) for glaucoma: Isolated-check VEP (icVEP) shows promising diagnostic accuracy in a 2025 meta-analysis (pooled sensitivity 77% and specificity 93%) but heterogeneity and limited high-quality trials limit generalizability; further research is required before broad adoption.

For PKG use, document duration of recording (e.g., PKG ≥ 6 days) and how findings changed management.

Correlate device outputs with clinical assessment and note any referral or therapeutic changes prompted by device data.

Prior Authorization

Limited-evidence devices — authorization likely required

Wearable sEMG seizure monitoring systems and certain visual evoked potential devices have limited evidence; prior authorization may be required and claims may be reviewed due to variable device performance and insufficient evidence for broad diagnostic use.

sEMG seizure monitors show feasibility for GTCS detection but have variable sensitivity, high false alarm rates, and device-related adverse events—document placement, algorithm performance, and adverse events if used.
Visual evoked potentials for glaucoma show promising results in some studies but overall evidence is weak—expect possible review/authorization requirements.

Prior Authorization

Prior authorization/coverage review for unproven NCS

Nerve conduction studies performed for indications not listed as proven (or performed using non‑invasive automated/point‑of‑care distal-only systems) may be subject to prior authorization or claim review and may be considered unproven/not medically necessary.

Claims for NCS for conditions other than the specifically listed proven indications may be denied or require review.
Automated/portable point-of-care NCS systems that test only distal motor latencies/conduction velocities are considered unproven and may trigger review/denial.

Billing Rule

Coding changes may affect prior authorization

Coding updates in the policy (including removal of CPT/HCPCS codes 95999 and A9279) may affect prior authorization and claim submission; verify current code lists and payer requirements before requesting authorization or billing.

Confirm that codes removed from the policy (95999, A9279) are not being used on submissions.
Use the policy's applicable code lists for reference but verify payer-specific covered codes and authorization rules.

Step Therapy

Step therapy — not specified

No step therapy requirements are specified in this policy section.

Note

Expected clinical indications for EDX testing

Electrodiagnostic testing is indicated for focal neuropathies/entrapments, traumatic nerve lesions, generalized neuropathies, neuromuscular junction disorders, radiculopathy/plexopathy, myopathy, and for symptom‑based presentations when pretest evaluations are inconclusive.

Use NCS/EMG to localize focal lesions, evaluate traumatic nerve injury, assess generalized neuropathies (diabetic, metabolic, toxic, hereditary, immune-mediated), and evaluate suspected neuromuscular junction disorders.
Consider testing when clinical assessment and pre-test evaluations do not provide a definitive diagnosis.

Note

Miscellaneous — no specific action

No specific miscellaneous provider actions are detailed in this inventory item.

Step Therapy

Evidence and step therapy guidance — none mandated

The policy does not describe step therapy directives for altering diagnostic pathways; it notes that more robust evidence would be needed before changing standard diagnostic practices.

Device and modality adoption should await stronger evidence before implementing mandatory stepwise diagnostic changes.

Note

Provider action — placeholder

No summary provided for this placeholder inventory item.

Note

Provider actions — container placeholder

No summary provided for this provider-actions container placeholder.

Documentation Required

Document clinical history and performer qualifications

Provide a clinical history and physical exam correlation and document performer qualifications; testing should be complementary to the history/exam and conducted by appropriately trained personnel per AANEM recommendations.

Document the clinical differential diagnosis informed by history and exam.
Record that needle EMG was performed by a trained physician and that technicians (if used) were supervised by the EDX physician.

Documentation Required

Document supervision, data collection, and integrated reporting

Clinical and electrophysiologic data collection should be supervised by the EDX physician; document the differential diagnosis, tests performed, real‑time interpretation, and integrated reporting of NCS and EMG findings.

Ensure one attending physician supervises and performs components of the exam and that reporting integrates NCS and EMG findings (separate reports are inappropriate).
Document any immediate physician reassessment prompted by unusual or unexpected test results.

Documentation Required

Document device data and interpretation

When wearable or objective device measurements are used to inform management, include device type, duration of recording, how device findings influenced management decisions, and clinician interpretation correlating device data with clinical status.

For PKG, document duration (e.g., ≥ 6 days) and specify any management changes based on PKG results.
Note limitations of device data and any device-related adverse events.

Documentation Required

QST documentation — calibration and protocol

For QST, document instrument calibration, the testing protocol used, and subject cooperation because QST results depend on methodology and reproducibility.

Record machine calibration details, stimulus parameters, and any factors affecting subject cooperation or test validity.
Avoid relying on QST as the sole diagnostic method.

Documentation Required

Document sEMG monitoring placement and algorithm performance

When using sEMG for seizure monitoring, document device placement (for example, biceps midline), detection algorithm performance, false alarm characteristics, and any adverse events such as skin irritation.

Include detection sensitivity, positive predictive value, mean false alarm rate, and any placement-dependent performance notes.
Document any device-related adverse events and their resolution.

Documentation Required

Document clinical indication for NCS

Ensure documentation supports the diagnosis or clinical indication for which nerve conduction studies are performed, referencing the policy's listed proven indications (e.g., peripheral neuropathy, plexopathy, neuromuscular junction disorders, myopathy).

Record specific clinical signs, test rationale, and how NCS/EMG results address the differential diagnosis.
Note any patient-specific factors (e.g., anticoagulation, lymphedema) that influenced the decision to perform NCS without needle EMG.

Documentation Required

Documentation requirements for pediatric NCS/EMG

For pediatric nerve conduction studies, document that testing supports one of the listed proven pediatric indications (per policy), such as peripheral neuropathy, plexopathy, neuromuscular junction disorders, or myopathy.

Include age-specific clinical rationale and correlation with examination findings.
Document whether needle EMG was performed and how results contributed to diagnosis or management.

Denial Risk

Denial risk — unproven tests and devices

Services and devices listed as unproven and not medically necessary (including macro‑EMG, sEMG, sMMG, QST CPT codes 0106T–0110T, visual evoked potential for glaucoma, and non‑invasive point‑of‑care NCS devices) are subject to denial if submitted as established medically necessary services.

Do not submit claims for these modalities as medically necessary without documentation demonstrating exceptional medical necessity and prior authorization if required.
Expect claim denial or review for automated/portable NCS systems that test only distal motor latencies/conduction velocities.

Denial Risk

Denial risk — meet AANEM performance and supervision standards

Failure to meet AANEM performance and supervision standards (medically indicated testing, appropriate equipment, physician supervision, and physician-performed needle EMG) could result in noncompliance or claim denial.

Ensure one attending physician supervises and that testing equipment is not screening‑only.
Document training/certification or accreditation status of performing personnel and laboratory when available.

Denial Risk

QST limitation — do not use as sole diagnostic test

QST should not be used as the sole diagnostic method; reliance solely on QST without corroborating clinical and electrophysiologic data may be inappropriate and subject to review.

Combine QST results with history, examination, and other diagnostic studies; document calibration and testing protocol when QST is used.

Denial Risk

sNCT considered investigational — denial risk

Current perception threshold / sensory nerve conduction threshold testing (sNCT) is considered investigational per AANEM model policy; submissions for sNCT may be denied as investigational.

Document any investigational rationale and obtain prior authorization if the payer requires review for investigational tests.

Denial Risk

Denial risk — unproven NCS and automated/portable devices

Claims for nerve conduction studies performed for conditions outside the policy's listed proven indications, and claims for non‑invasive automated/portable/automated point‑of‑care NCS systems that test only distal motor latencies and conduction velocities, may be denied or require prior review.

When performing NCS outside listed indications, document clinical justification and consider preauthorization.
Avoid using automated distal-only point‑of‑care devices as substitutes for standard NCS/EMG without documented justification.

Denial Risk

Denial risk — NCS for non‑listed conditions

Claims for nerve conduction studies for indications other than those specifically listed as proven (or for automated point‑of‑care systems testing only distal motor latencies/conduction velocities) may be considered unproven and not medically necessary and therefore denied.

Confirm that the clinical indication matches the policy's proven indications before billing, and secure prior authorization where required for atypical uses.

Used for monitoring muscle activity in respiratory support, trunk assessment, seizure detection (wearable sEMG), and other functional evaluations.

Evidence limitationOverall evidence for clinical efficacy of sEMG and SEMG‑based seizure monitoring systems is weak and variable; device performance depends on placement and algorithms.

Nerve Conduction Studies (NCS) — Definition

DefinitionNerve conduction studies (NCS) measure conduction velocity, latency, amplitude, and shape of peripheral nerve responses to assess peripheral nervous system integrity.

Late responses includedLate response testing (F‑wave and H‑reflex) are complementary NCS studies performed during the same evaluation and may be the only abnormality in some cases.

Typical pairingA properly performed electrodiagnostic evaluation generally involves both NCS and needle EMG per AANEM guidance.

QST — Quantitative Sensory Testing definition

DefinitionQuantitative sensory testing (QST) is a noninvasive psychophysical method that objectively assesses peripheral sensory nerve function by measuring responses to stimuli such as touch, vibration, and temperature.

ScopeQST evaluates large‑ and small‑fiber modalities and includes monofilaments, vibration, thermal testing, pressure‑specified devices, and current perception threshold (sNCT/CPT) methods.

LimitationsQST is highly dependent on methodology, instrument calibration, and subject cooperation; abnormal results do not localize pathology and should not be used as the sole diagnostic test.

mfVEP — Multifocal visual evoked potential testing definition

DefinitionMultifocal visual evoked potential (mfVEP) testing assesses multiple visual field locations independently and concurrently to produce a topographical representation of visual pathway defects.

Use casemfVEP and other VEP variants have been investigated for glaucoma detection and monitoring as an objective electrophysiological measure of visual pathway function.

Evidence limitationEvidence for VEPs in glaucoma is weak overall; icVEP meta‑analysis showed promising sensitivity/specificity but heterogeneity and limited trials warrant further research.

Real-time onsite EDX testing — Definition

DefinitionReal‑time onsite electrodiagnostic (EDX) testing integrates history and physical examination, performance of tailored NCS and needle EMG studies, and contemporaneous waveform analysis while the patient is present.

Performance standardAANEM recommends one attending physician supervise and perform all components of the exam on the same day, with integrated reporting of NCS and EMG results.

RationaleReal‑time interpretation ensures examination is tailored to clinical findings and that needle EMG studies complement NCS to develop the differential diagnosis.

GTCS/FBTCS — Seizure type definitions (wearable device context)

GTCSGeneralized tonic‑clonic seizure (GTCS): a seizure type for which validated wearable devices are recommended conditionally for automated detection when safety concerns exist.

FBTCSFocal bilateral tonic‑clonic seizure (FBTCS): focal onset seizures evolving to bilateral tonic‑clonic activity; wearable device recommendations mirror GTCS guidance.

Device scopeCurrent wearables are not recommended for seizure types other than GTCS/FBTCS due to limited evidence and variable performance.

QST (alternate) — Psychophysical testing definition

DefinitionQST (psychophysical) refers to tests measuring vibration, thermal, pressure, and other sensory thresholds to assess large‑ and small‑fiber sensory modalities.

CharacteristicsThese psychophysical tests depend on subject cooperation and standardized protocols; results do not localize lesions along the sensory axis.

Clinical roleQST may document sensory abnormalities and be useful in research and select clinical situations but lacks definitive evidence to be a standalone diagnostic test.

Quantitative Sensory Testing (QST) — Additional definition and limitations

DefinitionQuantitative Sensory Testing evaluates large‑ and small‑fiber sensory function using standardized stimuli to measure sensory thresholds.

LimitationsResults depend on instrument calibration, protocol reproducibility, and subject cooperation; different instruments have different specifications and norms.

InterpretationAbnormal QST does not localize dysfunction and should be interpreted alongside clinical examination and other diagnostic studies.

Surface Electromyography (sEMG) — Definition and common uses

DefinitionSurface electromyography (sEMG) is noninvasive recording of muscle electrical activity via skin electrodes used for monitoring and diagnostic assessments.

Common usessEMG applications include respiratory muscle monitoring, trunk muscle assessment, ALS monitoring, temporomandibular disorder evaluation, and wearable seizure detection.

Evidence and performancesEMG‑based seizure detection can reach high sensitivity when optimally placed but shows high false alarm rates and device‑related adverse events in trials.

Isolated-check Visual Evoked Potential (icVEP) — Definition

DefinitionIsolated‑check visual evoked potential (icVEP) measures visual pathway responses (signal‑to‑noise ratio) to detect glaucomatous changes.

Diagnostic performance noteMeta‑analysis reported pooled icVEP sensitivity 77% and specificity 93%, but heterogeneity and limited high‑quality trials limit generalizability.

Use considerationicVEP may be promising as an adjunctive objective test for glaucoma detection but requires further validation before routine clinical adoption.

EMG device class

ClassificationElectromyography (EMG) devices are regulated by the FDA as Class II medical devices (product code IKN referenced).

ReferenceFDA product code IKN is cited for EMG devices; manufacturers and users can refer to FDA listings for device details.

Regulatory implicationClass II classification indicates general controls and special controls apply to EMG device clearance and marketing.

Point-of-care nerve conduction device — Product code and status

Product codeAutomated point‑of‑care nerve conduction devices are classified under FDA product code JXE and have received 510(k) clearance in several cases.

Device natureThese portable devices rapidly evaluate peripheral nerve function using surface electrodes and built‑in software without producing real‑time waveforms.

Policy notePoint‑of‑care NCS devices are intended for screening and are not a substitute for full electrodiagnostic testing per the policy.

Nerve conduction studies (NCS) — Definition (including late responses)

DefinitionNCS measure conduction velocity, latency, amplitude and response shape of peripheral nerves; late responses (F‑wave, H‑reflex) are standard complementary tests.

Clinical roleLate responses can be the sole abnormality in some conditions (e.g., F‑wave/H‑reflex abnormalities in radiculopathy) and are performed during the same evaluation.

IntegrationNCS are typically integrated with needle EMG in a complete electrodiagnostic evaluation per AANEM standards.

Non-invasive automatic/portable NCS systems — Definition and policy stance

DefinitionNon‑invasive automatic/portable NCS systems are automated point‑of‑care devices that test distal motor latencies and conduction velocities without producing real‑time waveforms.

Evidence stanceThese systems are listed as unproven and not medically necessary for electrodiagnostic testing due to insufficient evidence and inability to replace full NCS/EMG.

Practical limitationBecause they do not provide real‑time waveform analysis and are designed for screening, they are not acceptable substitutes for properly performed EDX studies.

2026-05-01unproven_tests_listed

Listed multiple modalities as unproven and not medically necessary due to insufficient evidence, including macro-EMG, wearable physiologic seizure/movement monitors, SEMG, sMMG, quantitative sensory testing, and visual evoked potential testing for glaucoma.

2026-05-01coding_change

Removed CPT/HCPCS codes 95999 and A9279 from the applicable codes section.

2026-05-01administrative_update

Updated Description of Services, Clinical Evidence, FDA, and References sections and archived prior policy version CS082KY.11.

Note

Material changes effective 05/01/2026 — update practices

Summary of material changes effective 05/01/2026: added pediatric proven NCS + EMG indications and other revisions—review documentation and coding practices to align with updated policy.

Added proven/medically necessary pediatric indications for NCS/EMG (per Summary of Changes, effective 05/01/2026).
Review updated Description of Services, Clinical Evidence, FDA, and References sections and archived prior policy version CS082KY.11.

Note

Clarifications and unproven device stance

Policy clarifications note where NCS without needle EMG may be considered and list modalities deemed unproven; follow the clarified indications and avoid using unproven modalities as substitutes for standard testing.

NCS without needle EMG may be considered for radiculopathy, treatment guidance (muscle localization), anticoagulated patients, lymphedema, and carpal tunnel evaluation.
Macro‑EMG, SEMG, sMMG, non‑invasive point‑of‑care distal‑only NCS systems, QST modalities listed, and VEPs for glaucoma are described as unproven/not medically necessary.

Billing Rule

Removed codes — verify code list before billing

CPT/HCPCS codes 95999 and A9279 have been removed from the applicable codes section; confirm current code lists when obtaining authorization or submitting claims.

Do not use removed codes (95999, A9279) for authorization requests or claims without payer confirmation.
Cross-check the policy's applicable codes section against payer billing requirements.

Note

Miscellaneous revisions — review supporting updates

Other miscellaneous revisions updated Description of Services, Clinical Evidence, FDA, and References and archived the prior policy version; review the supporting sections for background and implementation details.